VT PATENTES

BIOTECNOLOGÍA SANITARIA

Degeneración macular
Diabetes
Sistema nervioso
Sistema inmune

42

Vigilancia Tecnológica
4º trimestre 2023

Este Boletín de Vigilancia Tecnológica en Biotecnología aplicada al sector sanitario surge del trabajo conjunto entre la Oficina Española de Patentes y Marcas (OEPM), ASEBIO y la Plataforma Tecnológica Española de Mercados Biotecnológicos, y se encuadra dentro de una de las actividades de colaboración que la OEPM viene llevando a cabo con las referidas Plataformas para hacer llegar a las empresas, investigadores, y organizaciones que las integran una selección de las patentes más recientemente publicadas en determinados sectores tecnológicos.

Estos Boletines trimestrales, como el resto de los elaborados por la OEPM, ofrecen una información puntual, esquemática y de rápida lectura sobre una selección de las últimas patentes biotecnológicas publicadas en el mundo relativas a cuatro líneas de investigación concretas: Sistema Nervioso, Sistema Inmune, Diabetes y Degeneración Macular. A través del número de publicación de cada patente, un enlace permite consultar el documento completo e incluso poder disponer de una traducción de la descripción realizada con la herramienta Patent translate.

También incluyen noticias sobre actividades realizadas por la OEPM que puedan resultar de interés a los usuarios. Si se desea recibir este Boletín periódicamente basta con cumplimentar el correspondiente formulario de suscripción.

Se puede acceder al listado de solicitudes de patentes analizadas pulsando sobre las imágenes que aparecen a continuación.

Contenido

DEGENERACIÓN MACULAR

DIABETES

SISTEMA NERVIOSO

SISTEMA INMUNE

Degeneración Macular

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2023220756	CHARACTER BIOSCIENCES INC [US]	Therapeutic lipid processing compositions and methods for treating age-related macular degeneration
WO2023212727	UNIV TEXAS [US]	Compositions and methods for treating eye diseases
WO2023205788	THE US GOV AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS [US]; UNIV OF BUFFALO [US]	Enhanced hammerhead ribozymes and methods of use
WO2023201366	DYNO THERAPEUTICS INC [US]	Capsid variants and methods of using the same
WO2023199951	CELLUSION INC [JP]	Multipotent stem cell having anti-VEGF function and differentiated cell thereof
WO2023199828	DEXON PHARMACEUTICALS INC [JP]	Fine particle, prophylactic drug or therapeutic drug for neovascular eye disease, and method for improving neovascular eye disease
WO2023192459	UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION [US]	Adeno-associated virus vectors
WO2023240062	ADVERUM BIOTECHNOLOGIES INC [US]	Melanopsin variants for vision restoration
WO2023215806	REGENXBIO INC [US]	Vectorized anti-complement antibodies and complement agents and administration thereof
WO2023212273	GENENTECH INC [US]	Treatments for age-related macular degeneration
WO2023212298	BROADWING BIO LLC [US]	Bispecific antibodies and methods of treating ocular disease
WO2023227468	ANNEXIN PHARMACEUTICALS AB [SE]	Monomeric Annexin A5 for use in the treatment of macular oedema or retinal vein occlusion
WO2023212293	BROADWING BIO LLC [US]	Complement factor H related 4-specific antibodies and uses thereof

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2023217933	HOFFMANN LA ROCHE [CH]; HOFFMANN LA ROCHE [US]	Antibody that binds to VEGF-α and IL6 and methods of use
WO2023211857	LINEAGE CELL THERAPEUTICS INC [US]; HADASIT MED RES SERVICE [IL]	Methods and compositions for treating vision loss
WO2023177691	REGENERON PHARMA [US]; BAYER HEALTHCARE LLC [US]	Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders
WO2023175099	COMPLEMENT THERAPEUTICS LTD [GB]	Agents for treating complement-related disorders
WO2023215787	VST BIO CORP [US]	Compositions and methods for selective regulation of vascular permeability
WO2023201364	DYNO THERAPEUTICS INC [US]	Capsid variants and methods of using the same
WO2023186131	STARRYGENE THERAPEUTICS CO LTD [CN]	AAV vector encoding anti-VEGF-α and ANG-2 bispecific antibody
WO2023230657	MOUNT SPEC INVEST PTY LTD [AU]	Modified adeno-associated virus capsid proteins and methods thereof
WO2023167484	SEOUL NAT UNIV HOSPITAL [KR]	Composition for preventing or treating retinal degenerative disease containing exosomes extracted from mesenchymal stem cells

Diabetes

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2023234513	KOREA INST SCI & TECH [KR]	Sensor for detecting glutamine by using split glutamine-binding protein and use thereof
WO2023230521	UNIV NORTH CAROLINA CHAPEL HILL [US]; NATIONAL UNIV CORPORATION TOKYO UNIV OF AGRICULTURE AND TECHNOLOGY [JP]	D-β-Hydroxybutyrate dehydrogenases (BHBDhs) and their use for ketone monitoring
WO2023229263	UNIV NAT CHONNAM IND FOUND [KR]	Composition for preventing, treating, or improving metabolic diseases comprising *Lactobacillus plantarum* NCHBL-004 strain or culture medium thereof
WO2023225603	UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION [US]	Insulin promoter for gene therapy for type 2 diabetes mellitus
WO2023220555	ENDSULIN INC [US]	Variant preproinsulin and constructs for insulin expression and treatment of diabetes
WO2023219376	CHUN HYUN SOO [KR]	Natural composition for inhibiting production of carcinogenic N-nitrosamine in stomach and intestines and promoting production of nitric oxide in intestines, and use thereof
WO2023211814	ALBERT EINSTEIN COLLEGE OF MEDICINE [US]	Circulating levels of endothelial microRNA-155 predict new-onset diabetes in COVID-19 and long COVID
WO2023210683	NAT CENTER FOR GLOBAL HEALTH AND MEDICINE [JP]	Method for assessing risk of kidney function decline
WO2023210578	ORIZURU THERAPEUTICS INC [JP]	Maturing agent having both of ALK5 inhibitory activity and CDK8/19 inhibitory activity
WO2023208223	MOON GUANGZHOU BIOTECH CO LTD [CN]	Pharmaceutical composition, megasphaera, and use thereof
WO2023207106	SUZHOU NEBULA BIOLOGICAL TECH CO LTD [CN]	GLP-1/GIP receptor co-agonist, pharmaceutical composition comprising same, and use thereof

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2023207107	SUZHOU NEBULA BIOLOGICAL TECH CO LTD [CN]	GLP-1/GCG receptor co-agonist, pharmaceutical composition comprising same and use thereof
WO2023205850	UNIV MONASH [AU]	Method of producing insulin-producing cells
WO2023204564	MEDISPAN CO LTD [KR]; UNIV NAT CHONNAM IND FOUND [KR]	Composition comprising flagellin and immunoglobulin Fc fusion protein for treatment of liver disease or metabolic syndrome
WO2023185442	UNIV EAST CHINA NORMAL [CN]	Glucose-regulated gene expression loop control system and use thereof in regulating and controlling blood glucose
WO2023183953	UNIV VIRGINIA PATENT FOUNDATION [US]	Delivery of dissociated islets cells within microporous annealed particle scaffold to treat type 1 diabetes
WO2023182567	CAREGEN CO LTD [KR]	Peptide having antidiabetic activity, peptide complex, and use thereof
WO2023177132	UNIV KEIMYUNG IACF [KR]	Biomarker for diagnosis of pre-diabetes and diabetes, and use thereof
WO2023174370	BEIJING TUO JIE BIOPHARMACEUTICAL CO LTD [CN]	Human insulin analogue, and fusion protein thereof and medical use thereof
WO2023169594	UNIV SUN YAT SEN [CN]	Application of blood-derived sample in preparation of vesicles
WO2023171982	UNIV YONSEI IACF [KR]	Composition for preventing or treating obesity, diabetes, or NASH comprising SHLP2 as active ingredient
WO2023168430	UNIV CORNELL [US]	Engineered immunomodulatory accessory cells improve allogeneic islet transplantation without immunosuppression
WO2023167528	APTAMER SCIENCES INC [KR]; POSTECH RES & BUSINESS DEV FOUND [KR]	Insulin receptor-specific aptamer and use thereof

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2023205762	ABBOTT LAB [US]	Methods and compositions for slowing diabetes development or reducing a risk of diabetes
WO2023233017	SKILLCELL [FR]; CENTRE NAT RECH SCIENT [FR]; CT HOSPITALIER UNIVERSITAIRE MONTPELLIER [FR]; UNIV MONTPELLIER [FR]	Urinary branched-chain amino acids (uBCAAS) as insulin resistance biomarkers
WO2023227657	ECOLE NAT VETERINAIRE AGROALIMENTAIRE ET DE L'ALIMENTATION NANTES ATLANTIQUE ONIRIS [FR]	Method for obtaining extracellular vesicles from beta cells
WO2023212604	LAY SCIENCES INC [US]	Targeted anti-SGLT1 avian IgY antibodies as treatment of pre-diabetes, type 2 diabetes and gestational diabetes
WO2023212683	KRIYA THERAPEUTICS INC [US]	Insulin and glucokinase gene therapy compositions and its use for treating diabetes
WO2023208993	RANDOX LABORATORIES LTD [GB]	Biomarkers of diabetic nephropathy
WO2023209186	SERODUS APS [DK]	IL-4 derived peptide fragments for use in the treatment of diabetic nephropathy
WO2023209091	UNIV HEIDELBERG [DE]	Cyclic peptides and their use for the treatment of diseases associated with dicarbonyls like methylglyoxal
WO2023196765	LILLY CO ELI [US]	Process for preparing a GLP-1/glucagon dual agonist
WO2023180547	UNIV WUERZBURG J MAXIMILIANS [DE]	MHC Ib-mediated islet-antigen-specific immunosuppression as a novel treatment for type 1 diabetes
WO2023201311	HCW BIOLOGICS INC [US]	Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder
WO2023186131	STARRYGENE THERAPEUTICS CO LTD [CN]	AAV vector encoding anti-VEGF-α and ANG-2 bispecific antibody

Sistema Nervioso

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2023238869	UNIV NAT CORP TOKYO MEDICAL & DENTAL [JP]	Preventative agent or therapeutic agent for amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, spinocerebellar ataxia, aging-related degenerative or neurological disease, brain aging, or diseases associated with brain aging
WO2023232083	UNIV XIAMEN [CN]	Beta 2-microglobulin blocking peptide, and pharmaceutical composition and use thereof
WO2023232108	THE FIRST AFFILIATED HOSPITAL OF ZHEJIANG UNIV SCHOOL OF MEDICINE [CN]; UNIV ZHEJIANG [CN]	Method, system, composition, and kit for diagnosing and identifying non-Alzheimer's disease cognitive disorder
WO2023230282	MASSACHUSETTS GEN HOSPITAL [US]; FOWLER ALAN JEROME [US]; TANZI RUDOLPH E [US]	Modulation of BACE1 as a therapy for spinocerebellar ataxia
WO2023229443	ZINCURE CORP [KR]	Novel peptide and use thereof
WO2023229363	UNIV KOREA RES & BUS FOUND [KR]; IAC IN NAT UNIV CHUNGNAM [KR]; KOREA RES INST BIOSCIENCE & BIOTECHNOLOGY [KR]	Amyotrophic lateral sclerosis animal model using transgenic zebrafish and construction method therefor
WO2023228155	D&D PHARMATECH INC [KR]	Compositions and methods for treatment of neurological disorders
WO2023225125	NEUVIVO INC [US]; UNIV CALIFORNIA [US]	Biomarkers for neurogenerative disease
WO2023225004	BIOSCREENING & DIAGNOSTICS LLC [US]	Prediction of Alzheimer's disease
WO2023220386	CHILDRENS HOSPITAL PHILADELPHIA [US]	Adeno-associated viral vectors for targeting brain microvasculature
WO2023220118	REGENERATIVE RES FOUNDATION [US]	Compositions and methods for controlled protein degradation in neurodegenerative disease

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2023215546	CAPSIDA INC [US]	Adeno-associated virus compositions having increased brain enrichment
WO2023214833	IMMUNOFORGE CO LTD [KR]	Fusion protein comprising GLP-1, immunoglobulin Fc, and IGF-1 and use thereof
WO2023214512	JOSHO GAKUEN EDUCATIONAL FOUND [JP]; UNIV HOKKAIDO NAT UNIV CORP [JP]	Artificial RNA molecule
WO2023212663	UNIV CALIFORNIA [US]	Pathology-responsive recombinant cells and uses thereof
WO2023212744	MASSACHUSETTS GEN HOSPITAL [US]; SADRI VAKILI GHAZALEH [US]; CUDKOWICZ MERIT E [US]; BERRY JAMES D [US]; PETROZZIELLO TIZIANA [US]; VAKILI KHASHAYAR [US]; FRAENKEL ERNEST [US]; RAGHAV YOGINDRA [US]; DILLIOTT ALLISON [CA]; FARHAN SALI [CA]; TALKOWSKI MICHAEL E [US]; GAO DADI [US]; PINTO RICARDO MOURO [US]	Gene fusions associated with amyotrophic lateral sclerosis (ALS)
WO2023211064	HELIXMITH CO LTD [KR]	AAV vector optimized for intrathecal administration into which hepatocyte growth factor gene is introduced
WO2023206759	SHENZHEN INST OF ADV TECH CAS [CN]	Alzheimer's disease biomarker and application thereof
WO2023206739	SHENZHEN INST OF ADV TECH CAS [CN]	Feces-based biomarker of Alzheimer's disease and use thereof
WO2023205854	UNIV MELBOURNE [AU]; AUSTRALIAN NATIONAL UNIV [AU]; FLOREY INST OF NEUROSCIENCE AND MENTAL HEALTH [AU]; UNIV DEAKIN [AU]	Hydrogel and uses thereof
WO2023205354	UNIV TEXAS TECH SYSTEM [US]	Synaptosomal micro RNAs and synapse functions in Alzheimer's disease
WO2023204381	SAMSUNG LIFE PUBLIC WELFARE FOUNDATION [KR]; RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIV [KR]; UNIV DONGGUK IND ACAD COOP [KR]	Method for providing information for predicting risk group for developing Alzheimer's disease or risk group for early onset of Alzheimer's symptoms, or risk group for developing amnestic mild cognitive impairment and/or pet-positive risk group for amyloid β deposition, based on european-east asian data

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2023204313	UNIV NIIGATA [JP]	TDP-43 aggregation suppressing agent and pharmaceutical composition
WO2023201511	SHENZHEN INST ADV TECH [CN]; SHENZHEN INST OF ADV TECH CAS [CN]	Biomarker for early diagnosis of Alzheimer's disease and use thereof
WO2023201316	UNIV TEXAS [US]; AUTOIMMUNITY BIOLOGIC SOLUTIONS INC [US]	Anti-soluble interleukin-7 receptor antibody therapy to treat autoimmune diseases
WO2023201322	SHIFT PHARMACEUTICALS HOLDING INC [US]; UNIV MISSOURI [US]	Compositions for and methods creating exon-skipped mRNA producing internal controls
WO2023201300	SHIFT PHARMACEUTICALS HOLDING INC [US]; UNIV MISSOURI [US]	Polynucleotide treatments for Charcot-Marie-Tooth disease
WO2023200281	DAEGU GYEONGBUK INST SCIENCE & TECH [KR]; KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND [KR]; UNIV CHOSUN IACF [KR]	Unagglomerated dissolving composition for diagnosis of Alzheimer's disease or mild cognitive impairment, and diagnostic method using same
WO2023196841	UNIV JOHNS HOPKINS [US]	Methods and materials for treating SYNGAP1-associated neurodevelopmental disorders
WO2023196470	UNIV CALIFORNIA [US]	Methods for treating Alzheimer's disease
WO2023190316	UNIV KYOTO [JP]	Preventive or therapeutic agent for neurodegenerative disease
WO2023186062	PREMIER BIO TECH LTD [CN]	Use of peptide in treating neurodegenerative disease or ameliorating cognitive function
WO2023184473	PREMIER BIO TECH LTD [CN]	Use of peptide in treating neurodegenerative diseases or improving cognitive function
WO2023183582	CAPSIDA INC [US]; WHEELER BRANDON G [US]; SHI XIAOJING [US]; GOEDEN NICHOLAS S [US]; FLYTZANIS NICHOLAS C [US]; SANDBERG TROY E [US]	Selected AAV compositions having preferred brain enrichment

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2023182801	THERABEST CO LTD [KR]	Pharmaceutical composition for preventing or treating degenerative brain disease comprising natural killer cell
WO2023182507	UNIV SAPPORO MEDICAL [JP]; ONODERA MEDICAL CO LTD [JP]	Pharmaceutical composition, method for producing three-dimensional culture of mesenchymal stem cells, method for producing exosomes, and method for producing pharmaceutical composition
WO2023182243	DEXON PHARMACEUTICALS INC [JP]	Gene expression regulator, prophylactic drug or therapeutic drug for Alzheimer's disease, and method for improving dementia
WO2023178109	RESONANT LLC [US]	Neuronal methylation signatures from cell free DNA as a pre-symptomatic neurodegenerative condition surveillance diagnostic
WO2023178241	UNIV COLORADO REGENTS [US]	Methods and compositions for disrupting tau aggregates using polyserine repeat sequences targeting exogenous proteins
WO2023177682	UNIV MICHIGAN REGENTS [US]	Compositions and methods for analysis, detection, and treatment of multiple sclerosis
WO2023177056	SAMSUNG LIFE PUBLIC WELFARE FOUNDATION [KR]; RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIV [KR]; UNIV DONGGUK IND ACAD COOP [KR]	Method for providing information for predicting risk group for developing Alzheimer's disease or risk group for early onset of Alzheimer's symptoms, or risk group for developing amnestic mild cognitive impairment and/or pet-positive risk group for amyloid β deposition, based on european population data
WO2023175225	UNIV MIGUEL HERNANDEZ DE ELCHE [ES]; CONSEJO SUPERIOR INVESTIGACION [ES]; CONSORCIO CENTRO DE INVESTIG BIOMEDICA EN RED [ES]	Method and kit for diagnosing Alzheimer's disease based on the detection of apolipoprotein e

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2023173061	UNIV MASSACHUSETTS [US]	Oligonucleotides for APP modulation
WO2023173009	JACKSON LAB [US]	Wild-derived mouse models of Alzheimer's disease
WO2023171828	ALZMED INC [KR]	Novel Alzheimer model and construction method therefor
WO2023171587	OHARA PHARMACEUTICAL CO LTD [JP]	Modified siRNA for selectively inhibiting expression of mutant FUS
WO2023240274	MEDICAL COLLEGE WISCONSIN INC [US]; VERSITI BLOOD RES INSTITUTE INC [US]	Immune tolerance induction for auto-immune diseases through platelet targeted gene therapy involving myelin oligodendrocyte glycoprotein (MOG) polypeptide.
WO2023220349	DICERNA PHARMACEUTICALS INC [US]	Compositions and methods for inhibiting MAPT expression
WO2023222924	PASTEUR INSTITUT [FR]	*Lachnospiraceae* SPP and *Ruminococcus lactaris* strains for the treatment and prevention of Alzheimer's disease and aging
WO2023222858	HOFFMANN LA ROCHE [CH]; HOFFMANN LA ROCHE [US]	Improved oligonucleotides targeting RNA binding protein sites
WO2023201311	HCW BIOLOGICS INC [US]	Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder
WO2023205637	LOCANABIO INC [US]	RNA-targeting compositions and methods for treating C9/ORF72 diseases
WO2023217890	HOFFMANN LA ROCHE [CH]; HOFFMANN LA ROCHE [US]	Antisense oligonucleotides targeting CFP-ELK1 intergene region
WO2023201277	REGENXBIO INC [US]	Recombinant adeno-associated viruses for CNS tropic delivery
WO2023198985	UNIV GRENOBLE ALPES [FR]; INST NAT SANTE RECH MED [FR]	Peptide suitable for transporting molecules across cell barriers

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2023196619	SHAPE THERAPEUTICS INC [US]; TOME JACOB MICHAEL [US]; SULLIVAN RICHARD THOMAS [US]; KALL STEPHANIE [US]; SHANNON SANDRA BLAIR [US]	Promoter switches for tissue-specific expression
EP4286010	TG THERAPEUTICS INC [US]; LAB FRANCAIS DU FRACTIONNEMENT [FR]	Anti-CD20 antibody compositions
EP4286414	TG THERAPEUTICS INC [US]; LAB FRANCAIS DU FRACTIONNEMENT [FR]	Anti-CD20 antibody compositions
WO2023198828	UNIV AUTÒNOMA DE BARCELONA [ES]; CONSORCIO CENTRO DE INVESTIG BIOMEDICA EN RED [ES]; INST CATALANA RECERCA ESTUDIS AVANCATS [ES]; FUNDACIO HOSPITAL UNIV VALL DHEBRON INSTITUT DE RECERCA [ES]	Treatment of neuromuscular diseases via gene therapy that expresses klotho protein
WO2023198960	UNIV OF EASTERN FINLAND [FI]	A biomarker for determining Alzheimer's disease
WO2023192288	DENALI THERAPEUTICS INC [US]	Monovalent anti-TREM2 binding molecules and methods of use thereof
WO2023183623	REGENXBIO INC [US]	Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
WO2023198702	UNIQURE BIOPHARMA B V [NL]	Nucleic acid regulation of C9ORF72
WO2023198745	UNIQURE BIOPHARMA B V [NL]	Nucleic acid regulation of APOE
WO2023194565	AC IMMUNE SA [CH]	Anti-TDP-43 binding molecules
WO2023180546	UNIV WUERZBURG J MAXIMILIANS [DE]	MHO Ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and MOG antibody disease
WO2023174838	HOFFMANN LA ROCHE [CH]; HOFFMANN LA ROCHE [US]	Modulators of the G3BP2-Tau interaction for the treatment of Tau associated diseases
WO2023201133	UNIV NEBRASKA [US]	Cell therapy for Alzheimer's disease
WO2023170307	ADMIT THERAPEUTICS SL [ES]	Methods of determining the risk of developing Alzheimer's disease dementia

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2023214189	INST NAT SANTE RECH MED [FR]; CENTRE NAT RECH SCIENT [FR]; UNIV CLAUDE BERNARD LYON [FR]; UNIV JEAN MONNET SAINT ETIENNE [FR]	Method and composition for treating neurodegenerative disorder
WO2023187205	GREENTECH [FR]	*Parabacteroides distasonis* strain isolated from human feces and applications thereof
WO2023180547	UNIV WUERZBURG J MAXIMILIANS [DE]	MHC Ib-mediated islet-antigen-specific immunosuppression as a novel treatment for type 1 diabetes

Sistema Inmune

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2023224554	NAT UNIV SINGAPORE [SG]	An engineered probiotic produces a type III interferon IFNL1 and reduces inflammations in *in vitro* inflammatory bowel disease models
WO2023225153	JACKSON LAB [US]	Transgenic mouse models of human adaptive and innate immunity and methods of use
WO2023225667	SYNLOGIC OPERATING CO INC [US]	Recombinant bacteria for production of indole-3-acetic acid (IAA) and uses thereof
WO2023220750	ANNEXON INC [US]; ARTIS DEAN R [US]; ANDREWS ZWILLING YAISA [US]	Compositions and methods for treating lupus nephritis
WO2023220745	DERMTECH INC [US]	Novel expression based, non-invasive method to differentiate atopic dermatitis and psoriasis
WO2023220658	CODEXIS INC [US]	Recombinant neprosin polypeptides and methods of expression
WO2023219175	UNIV TOKYO [JP]	Method and composition both for treating or diagnosing inflammatory bowel disease (IBD)
WO2023215331	AMPEL BIOSOLUTIONS LLC [US]	Methods and compositions for assessing and treating lupus
WO2023212443	BIOMARCK PHARMACEUTICALS LTD [US]	Peptides and methods of use thereof in treating skin diseases

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2023211228	MIRIMGENE CO LTD [KR]	Pharmaceutical composition comprising anti-WARS1 antibody for preventing or treating inflammatory diseases
WO2023211198	NOVACELL TECH INC [KR]	Novel anti-inflammatory peptide and use thereof
WO2023205711	REPLAY HOLDINGS INC [US]	Methods and compositions for cellular therapy
WO2023204562	MEDISPAN CO LTD [KR]; UNIV NAT CHONNAM IND FOUND [KR]	Composition for treating colitis, comprising flagellin and immunoglobulin Fc fusion protein
WO2023201243	BAYLOR COLLEGE MEDICINE [US]	Bacterial biosensors for diagnosing and treating inflammation
WO2023200203	SEOUL NAT UNIV R&DB FOUNDATION [KR]	Novel microorganism and composition comprising same
WO2023196970	UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION [US]	Matrix bound nanovesicles encapsulated in hydrogels
WO2023182868	CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION [KR]	Pathogenic vimentin expression induction and infectious disease-associated autoimmune fibrosis disease patient drug screening platform model
WO2023178645	GENOR BIOPHARMA CO LTD [CN]	CD3-targeting antibody and use thereof
WO2023178306	FAB BIOPHARMA INC [US]	Compositions and methods for treatment of Sjögren's syndrome and/or systemic lupus erythematosus
WO2023167563	KOREA RES INST BIOSCIENCE & BIOTECHNOLOGY [KR]	Composition containing N-carbamyl-L-glutamic acid for treatment of inflammatory diseases
WO2023239728	EVELO BIOSCIENCES INC [US]	Compositions and methods of treating inflammation using *Prevotella histicola* extracellular vesicles

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2023220663	PFIZER [US]; BRISTOL MYERS SQUIBB CO [US]	Anti-TL1A antibodies and methods of use thereof
WO2023237687	DSM IP ASSETS BV [NL]	Combinations comprising vitamin B2 and *Lactobacillus rhamnosus*
WO2023227641	GLAXOSMITHKLINE IP DEV LTD [GB]	Use of TNF-alpha binding proteins and IL-7 binding proteins in medical treatment
WO2023228082	PFIZER [US]	Anti-TNFR2 antibodies and methods of use thereof
WO2023218177	UCL BUSINESS LTD [GB]	Biomarkers
WO2023217743	IMCHECK THERAPEUTICS [FR]	Anti-BTN3A antibodies for use in methods of treating gastro-intestinal inflammatory disorders
WO2023205617	LILLY CO ELI [US]	Antibodies and methods targeting interleukin-19
EP4286010	TG THERAPEUTICS INC [US]; LAB FRANCAIS DU FRACTIONNEMENT [FR]	Anti-CD20 antibody compositions
WO2023183766	ABCELLERA BIOLOGICS INC [CA]; BARNHART BRYAN CRAWFORD [CA]	Anti-CD3 antibodies and T-cell engagers and methods of use
WO2023187422	REVOLO BIOTHERAPEUTICS LTD [GB]	Compositions and their use in methods for treating intestinal inflammation
WO2023180767	HEPTARES THERAPEUTICS LTD [GB]	Anti-PAR2 antibodies
WO2023186193	CONTIPRO AS [CZ]	Hexapeptide, composition comprising thereof and topical use thereof
WO2023187205	GREENTECH [FR]	Parabacteroides distasonis strain isolated from human feces and applications thereof
WO2023187707	JANSSEN BIOTECH INC [US]	Method of treating mild to moderate psoriasis with IL-23 specific antibody

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2023180953	GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 3 LTD [GB]	Inhibitors of human SLC7A3 for the treatment of endometriosis or uterine fibroids
WO2023180276	NETRIS PHARMA [FR]	Anti-netrin-1 antibody against arthritis-associated pain
WO2023175177	INST CURIE [FR]; CENTRE NAT RECH SCIENT [FR]; UNIV SORBONNE [FR]	Differential diagnosis of Crohn's disease and ulcerative colitis
WO2023170045	UNIV LJUBLJANI [SI]; UNIV WIEN MED [AT]; HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH [DE]	Method for diagnosing endometriosis in a subject
EP4269620	PHADIA GMBH [DE]	Methods, devices and systems for determining a presence or absence of genetic markers of rheumatoid arthritis and determining a risk of developing rheumatoid arthritis in an individual
EP4265737	ACAD MEDISCH CT [NL]	Methylation markers for predicting sensitivity to treatment with antibody based therapy
WO2023183434	ARTISAN DEV LABS INC [US]	Compositions and methods for generating cells with reduced immunogenicty
WO2023201311	HCW BIOLOGICS INC [US]	Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder
WO2023170241	UNIV LOUVAIN [BE]	TGF-β antibodies
WO2023170435	MINA THERAPEUTICS LTD [GB]; SKOURTIS STATHAKI KONSTANTINA [US]	IL10 saRNA compositions and methods of use

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2023169594	UNIV SUN YAT SEN [CN]	Application of blood-derived sample in preparation of vesicles
WO2023214387	DUCENTIS BIOTHERAPEUTICS LTD [GB]	Novel CD200 fusion proteins

Noticias

PUESTA EN MARCHA DE NUEVO SISTEMA DE SOLICITUD ELECTRÓNICA DE INVENCIONES (OEPMSEI)

Desde principios del mes de noviembre, la OEPM tiene un nuevo sistema de presentación electrónica de invenciones, OEPMSEI. Con esta aplicación, desarrollada de la mano de la Oficina Europea de Patentes, queremos dar solución a una de las mayores demandas de nuestro colectivo de usuarios: modernizar y hacer más amigables e intuitivos nuestros sistemas de solicitud electrónica de las diferentes modalidades de invenciones.

El alcance de esta primera versión es limitado, incluyendo los siguientes trámites:

- Solicitud de patente nacional y de modelo de utilidad (incluyendo, además de la primera presentación, la solicitud divisional, la transformación de patente europea y el cambio de modalidad)
- Solicitud de validación de patente europea (provisional y definitiva)
- Solicitud de Certificado Complementario de Protección (CCP), incluyendo la presentación de prórrogas CCP para medicamentos pediátricos.
- Solicitud internacional PCT (formulario PCT/RO/101)
- Solicitud de Patente Europea (formulario 1001)
- Un número limitado de trámites subsiguientes, que pueden consultarse en la Sede Electrónica

Durante todo este proceso de modernización se seguirá manteniendo el sistema actual (e-OLF) de forma paralela, pero se irá restringiendo su acceso de forma progresiva hasta llegar a su apagado final, una vez se encuentren migrados todos los trámites necesarios.

El acceso a la aplicación requerirá la identificación electrónica mediante cl@ve o utilizando una EPO Smartcard.

Más información

LA OFICINA ESPAÑOLA DE PATENTES Y MARCAS LANZA SU CAMPAÑA ANUAL PARA ESTIMULAR LA COMPRA DE PRODUCTOS ORIGINALES

La Oficina Española de Patentes y Marcas, O.A. (OEPM) realiza anualmente, de acuerdo con Plan Anual de Publicidad Institucional de la Administración General del Estado, una campaña de concienciación y sensibilización sobre la falsificación de bienes y mercancías y sus consecuencias sociales y económicas. Este año 2023 la campaña ha comenzado el viernes 24 de noviembre para hacerla coincidir con el Black Friday, uno de los periodos punta anual de compras por parte de los consumidores, junto con la Navidad.

El acto de presentación de la campaña ha sido presidido por la Directora de la OEPM, Aida Fernández. Al mismo han asistido representantes del sector público relacionados con la lucha frente al fenómeno de las falsificaciones, como las Fuerzas y Cuerpos de Seguridad del Estado, y del sector privado como asociaciones de consumidores, o representantes de marcas, entre otros. Los representantes de la Unidad Vigilancia Aduanera de Madrid y del Consejo de Consumidores y Usuario destacaron la necesidad de continuar informando y sensibilizando al consumidor sobre el perjuicio y los riesgos del uso de falsificaciones.

La campaña de este año con el lema **EL DAÑO DE LAS FALSIFICACIONES ES REAL** pretende informar y concienciar de que el consumo de productos falsificados hace que se cierren negocios, se ponga en riesgo la salud, o se contribuya a la contaminación global.

La creatividad se basa en un diseño original e impactante en el que se mezclan los productos falsificados con sus efectos y daños reales, de forma que se integran con la técnica del collage para crear un efecto visual que muestra los impactos reales de la compra de productos falsificados.

En palabras de Amundsen, la agencia creativa "*el objetivo es mostrar al consumidor **la realidad de los daños que producen los productos falsificados** y hacerles conscientes de los mismos. A través de un **juego de palabras se pasa de lo falso a lo real** poniéndoles entre dos elecciones de manera directa. Les hacemos posicionarse. Queremos abrirles los ojos a través del impacto tanto visual como con el mensaje directo y que pone una realidad sobre la mesa*".

Más información

NUEVA EDICIÓN DEL CURSO DE GESTIÓN ADMINISTRATIVA DE LA PROPIEDAD INDUSTRIAL (PARALEGALES)

Una formación adecuada es uno de los pilares para hacer bien las cosas. Con este convencimiento, la Oficina Española de Patentes y Marcas, O.A. (OEPM) y la Escuela de Organización Industrial, F.S.P. (EOI) amparan la Cátedra de Innovación y Propiedad Industrial Carlos Fernández-Nóvoa, cuya finalidad última es facilitar la transferencia de conocimiento mutuo entre la empresa y las Universidades.

En este marco va a comenzar el próximo 22 de enero la 12ª edición del Curso de Gestión Administrativa de la Propiedad Industrial (Paralegales). Este curso, dirigido a profesionales de Agencias de la Propiedad Industrial, personal de Departamentos de Propiedad Industrial de empresas, OTRIS de Universidades, Parques Tecnológicos, y OPIS, etc. y en general a todos los profesionales interesados en la gestión de la Propiedad Industrial, tendrá lugar en formato virtual durante los meses de enero a mayo de 2024, y constará, como es habitual, de 5 módulos independientes.

La matriculación para cada módulo se puede realizar de forma independiente y es posible matricularse hasta la fecha de comienzo de cada uno de ellos.

Los principales objetivos del curso son:

- Ofrecer al participante una formación teórica y práctica en materia de Propiedad Industrial, invenciones, signos distintivos y diseños.
- Dar una formación en profundidad de todos los aspectos relevantes de los sistemas de protección españoles.
- Proporcionar formación continua y estructurada de los sistemas de protección internacionales: Europeo, PCT, USA, Chino, etc.
- Potenciar el intercambio de experiencias entre los diferentes sectores implicados a nivel nacional e internacional.

Más información:

Información e inscripciones
Programa

CONCESIÓN DE LAS AYUDAS PARA EL FOMENTO DE LAS SOLICITUDES DE PATENTES Y MODELOS DE UTILIDAD 2023

La Oficina Española de Patentes y Marcas, O.A. (OEPM) convoca todos los años unas ayudas con el fin fomentar las solicitudes de patentes y modelos de utilidad. La finalidad de estas ayudas es impulsar la utilización de la Propiedad por las empresas españolas para que sirva de herramienta de acceso a los mercados internacionales.

Estas ayudas, que corresponden a la convocatoria del año 2023, se concedieron el pasado 1 de diciembre.

Más información:

Noticia

Ayudas de la OEPM para el fomento de solicitudes de patentes y modelos de utilidad